He Junyun, Lai Huafang, Esqueda Adrian, Chen Qiang
The Biodesign Institute, Arizona State University, Tempe, AZ 85287, USA.
School of Life Sciences, Arizona State University, Tempe, AZ 85287, USA.
Vaccines (Basel). 2021 Jan 17;9(1):60. doi: 10.3390/vaccines9010060.
In this study, we developed a hepatitis B core antigen (HBcAg)-based virus-like particle (VLP) that displays the West Nile virus (WNV) Envelope protein domain III (wDIII) as a vaccine candidate for WNV. The HBcAg-wDIII fusion protein was quickly produced in plants and reached a high expression level of approximately 1.2 mg of fusion protein per gram of leaf fresh weight within six days post gene infiltration. Electron microscopy and gradient centrifugation analysis indicated that the introduction of wDIII did not interfere with VLP formation and HBcAg-wDIII successfully assembled into VLPs. HBcAg-wDIII VLPs can be easily purified in large quantities from leaves to >95% homogeneity. Further analysis revealed that the wDIII was displayed properly and demonstrated specific binding to an anti-wDIII monoclonal antibody that recognizes a conformational epitope of wDIII. Notably, HBcAg-wDIII VLPs were shown to be highly immunogenic and elicited potent humoral responses in mice with antigen-specific IgG titers equivalent to that of protective wDIII antigens in previous studies. Thus, our wDIII-based VLP vaccine offers an attractive option for developing effective, safe, and low-cost vaccines against WNV.
在本研究中,我们开发了一种基于乙肝核心抗原(HBcAg)的病毒样颗粒(VLP),该颗粒展示西尼罗河病毒(WNV)包膜蛋白结构域III(wDIII),作为WNV的候选疫苗。HBcAg-wDIII融合蛋白在植物中快速产生,在基因浸润后六天内达到约每克叶片鲜重1.2毫克融合蛋白的高表达水平。电子显微镜和梯度离心分析表明,wDIII的引入不干扰VLP的形成,并且HBcAg-wDIII成功组装成VLP。HBcAg-wDIII VLP可以很容易地从叶片中大量纯化至>95%的纯度。进一步分析表明,wDIII展示正确,并与识别wDIII构象表位的抗wDIII单克隆抗体表现出特异性结合。值得注意的是,HBcAg-wDIII VLP显示出高度免疫原性,并在小鼠中引发强烈的体液反应,抗原特异性IgG滴度与先前研究中保护性wDIII抗原的滴度相当。因此,我们基于wDIII的VLP疫苗为开发针对WNV的有效、安全和低成本疫苗提供了一个有吸引力的选择。